The promyelocytic leukemia (PML) tumor suppressor protein, a central regulator of cell proliferation and apoptosis, is frequently fused to the retinoic acid receptora (RARa) in acute PML. Here we show the interaction of PML with another tumor suppressor protein, the serine/ threonine kinase homeodomain-interacting protein kinase (HIPK2). In response to DNA damage, HIPK2 phosphorylates PML at serines 8 and 38. Although HIPK2-mediated phosphorylation of PML occurs early during the DNA damage response, the oncogenic PML-RARa fusion protein is phosphorylated with significantly delayed kinetics. DNA damage or HIPK2 expression leads to the stabilization of PML and PML-RARa proteins. The N-terminal phosphorylation sites contribute to the DNA damage-induced PML SUMOylation and are required for the ability of PML to cooperate with HIPK2 for the induction of cell death.
Introduction
The homeodomain-interacting protein kinase (HIPK) family of serine/threonine kinases comprises three members showing diverse functions ranging from the regulation of transcription to cell death (Rinaldo et al., 2007) . The best characterized member of the HIPK family is HIPK2, which binds to and phosphorylates homeobox transcription factors and also further accessory components of the transcription machinery (Calzado et al., 2007) . HIPK2 and its ability to trigger apoptosis are evolutionary conserved and already occur in Drosophila (Link et al., 2007) . Genetic evidence revealed that HIPK2 functions as a tumor suppressor that can regulate apoptosis by p53-independent and -dependent pathways (Wei et al., 2007) . In response to DNA damage induced by diverse agents including UV and ionizing radiation (D'Orazi et al., 2002; Hofmann et al., 2002) , cisplatin (Di Stefano et al., 2004) or adriamycin , HIPK2 is activated to phosphorylate p53 on serine 46, a modification that favours the expression of apoptosis-inducing genes (D'Orazi et al., 2002; Hofmann et al., 2002) . DNA damage-induced HIPK2 activation depends on the ATM (ataxia telangiectasia mutated) kinase (Dauth et al., 2007) , which is part of a protein complex that recognizes DNA double-strand breaks. HIPK2-mediated p53 phosphorylation and apoptosis induction depend on the presence of PML (Moller et al., 2003) . PML is a tumor suppressor that mainly localizes to punctate nuclear structures that are called PML nuclear bodies (PML-NBs), also known as PML oncogenic domains, Kremer bodies or ND10s (nuclear dot 10) (Maul et al., 2000; Dellaire and Bazett-Jones, 2004 ). This subnuclear localization of PML depends on a domain that allows non-covalent binding of SUMO (Shen et al., 2006) . PML has been implicated in a variety of biological functions including regulation of gene expression, apoptosis and senescence (Takahashi et al., 2004; Bernardi and Pandolfi, 2007) . The PML protein occurs in many differentially spliced forms that exert different functions, as for example, only the splice variant PML-IV promotes senescence in human diploid fibroblasts and recruits HIPK2 to PML-NBs (Bischof et al., 2002) . The human PML gene was identified as the fusion partner of the retinoic acid receptor-a (RARa) gene by the t(15;17) chromosomal translocation, which is causative for acute promyelocytic leukemia (PML) (de The et al., 1991) . The resulting PML-RARa fusion protein is a dominant negative inhibitor of the PML tumor suppressor protein and also interferes with RARa-mediated transcription and differentiation (Villa et al., 2007) . PML regulation is even more complex, as the PML gene is strongly induced by interferons, and the PML protein is heavily modified by posttranslational modifications including SUMOylation and phosphorylation (Bernardi and Pandolfi, 2007) . SUMO modification occurs at three lysines and contributes to its sequestration in NBs, proapoptotic function and the control of its stability (Kamitani et al., 1998; Shen et al., 2006; Lallemand-Breitenbach et al., 2008; Tatham et al., 2008) . Phosphorylation of PML can be mediated by diverse kinases including Chk2 (checkpoint kinase-2), CK2 (casein kinase 2), ERKs (extracellular-signal regulated kinases) and ATR (ATM and Rad3-related) (Yang et al., 2002; Bernardi et al., 2004; Hayakawa and Privalsky, 2004; Scaglioni et al., 2006) . We have previously shown that PML is required for HIPK2-mediated p53 phosphorylation (Moller et al., 2003) , and reveal in this study that PML is also an interaction partner and phosphorylation substrate of HIPK2. In response to DNA damage, HIPK2-mediated PML phosphorylation at serines 8 and 38 triggers SUMOylation of PML and its proapoptotic function.
Results

HIPK2 binds to and stabilizes the PML protein
The PML mediated recruitment of HIPK2 to PML-NBs prompted us to test a possible interaction between these proteins. Coimmunoprecipitation experiments revealed mutual interaction of very small subfractions of both partners ( Figure 1a ). Mapping experiments with HIPK2 mutants either lacking the N-terminal kinase domain or the C-terminal part of the protein showed binding of PML to the HIPK2 C terminus (Figure 1b ). PML and HIPK2 share many interaction partners including SP100 and p53, raising the question whether their interaction is direct. To address this issue, both proteins were produced by in vitro translation and examined for mutual binding. Coimmunoprecipitation experiments revealed direct interaction between both proteins ( Figure 1c) . To investigate the localization of HIPK2 within the PML-NBs in more detail, cells expressing GFP-HIPK2 and the PML isoform PML-IV were analysed by confocal microscopy. HIPK2 was quantitatively recruited by PML-IV ( Figure 1d ) and multiple image stacks were recorded to allow the analysis of the three-dimensional distribution pattern of PML and HIPK2. Three dimensional reconstruction of the NBs and surface rendering revealed the kinase in the center of PML-NBs, surrounded by PML that exclusively localizes in the periphery (Figure 1e ). The HIPK2DC mutant was not recruited to PML-NBs (Figure 1f ), indicating that binding of HIPK2 to PML is important for this recruitment. As HIPK2 activity is induced by DNA damage, we evaluated the impact of the DNAdamaging chemotherapeutic agent adriamycin on PML expression. Western blot experiments showed almost undetectable PML protein levels in untreated cells and significantly elevated PML amounts in adriamycintreated cells (Figure 2a ). Although PML induction was stronger in interferon-treated cells, these results reveal clearly increased PML levels in response to DNA damage. To study a possible contribution of HIPK2 to this stabilization, cells were transfected to express low amounts of PML-IV either alone or together with HIPK2 or a kinase inactive HIPK2 point mutant (K221A). Dependent on its kinase function, HIPK2 strongly enhanced adriamycin-mediated PML stabilization (Figure 2b ). This HIPK2-mediated stabilization was most prominent after the expression of low levels of PML. As in this experiment PML-IV is produced from a constitutively active promoter, the observed stabilization can occur on the protein level.
HIPK2 phosphorylates N-terminal serines of PML in response to DNA damage The possibility of a direct HIPK2-mediated PML phosphorylation was tested by in vitro kinase assays using different purified GST-PML fusion proteins spanning various portions of PML as substrates. Immunoprecipitated HIPK2 efficiently phosphorylated GST-PML (1-130), while it did not phosphorylate further GST fusion proteins covering more C-terminal parts of PML (Figure 3a) . Kinase inactive HIPK2 point mutant failed to trigger GST-PML (1-130) phosphorylation, suggesting that 32 P incorporation is directly caused by HIPK2 and not by another kinase coimmunoprecipitated with it. To determine the phosphorylation site, the HIPK2-phosphorylated GST-PML (1-130) protein was subjected to mass spectrometry (Supplementary Figure 1 ). These experiments revealed PML phosphorylation at serine 38, which is flanked by a proline as all HIPK2 phosphorylation sites identified so far (Calzado et al., 2007) . However, mutation of serine 38 still allowed to detect HIPK2-mediated in vitro phosphorylation of GST-PML (1-130) S38A (data not shown). To identify the modified amino acid, the in vitro phosphorylated GST-PML (1-130) S38A protein was analysed by mass spectrometry, which revealed that mutation of serine 38 prompts the phosphorylation of the neighboring serine 36 (Supplementary Figure 2) . In vitro kinase assays showed that mutation of serines 36 and 38 in the GST-PML (1-130) protein still allowed partial phosphorylation by HIPK2. A largely abrogated HIPK2-mediated phosphorylation of GST-PML (1-130) was only achieved upon additional mutation of serine 8, thus showing that HIPK2 can phosphorylate serines 8, 36 and 38 ( Figure 3b ). We then raised phospho-specific antibodies to detect serine 38 phosphorylation of the endogenous PML protein. The specificity of the antibody was tested in control experiments, which confirmed that a PML protein mutated at serine 38 was not recognized by the antibody (Supplementary Figure 3) . Immunofluorescence analysis showed that PML serine 38 phosphorylation occurred in NBs in response to DNA damage ( Figure 3c ). Confocal microscopy showed PML phosphorylation largely, but not exclusively, within PML-NBs ( Figure 3d ). Next, we tested the relevance of substrate binding for HIPK2-mediated stabilization and phosphorylation of PML. Cells were transfected to express PML-IV along with HIPK2 or HIPK2DC, followed by the analysis of PML phosphorylation and abundance by immunoblotting. These experiments revealed the inability of HIPK2DC to mediate stabilization and phosphorylation of PML (Figure 3e ). (Figure 4a). DNA damage also resulted in inducible PML serine 38 phosphorylation, which was significantly impaired in the presence of kinase inactive HIPK2, which acts as a dominant negative mutant. An earlier study showed that arsenic trioxide-induced PML serine 38 phosphorylation is mediated by ERKs (Hayakawa and Privalsky, 2004) .
To examine the relative contribution of ERKs for serine 38 phosphorylation in response to DNA damage, the experiment was repeated in the presence of the MEK inhibitor U0126, which efficiently blocks ERK activation. Whereas basal and induced ERK activation was completely inhibited by U0126, PML phosphorylation could still be induced by DNA damage and/or HIPK2 expression ( Figure 4a, upper panel) . A quantitative analysis of PML stabilization and phosphorylation revealed a dominant role of PML phosphorylation ( Figure 4a , lower panel). To investigate the relative contribution of HIPK2 for PML serine 38 phosphorylation, adriamycin-induced PML phosphorylation was compared between controls and cells, where endogenous HIPK2 was knocked down by shRNA (short hairpin RNA). These experiments revealed that a strong reduction of HIPK2 levels resulted in an impaired, but not an absent serine 38 phosphorylation (Figure 4b ), raising the possibility that further kinases can modify this site. As PML-RARa is biochemically and functionally distinct from PML, we tested whether HIPK2 can also induce phosphorylation of this oncogenic fusion protein. Cells expressing various combinations of PML-IV, PML-RARa or HIPK2 were left untreated or incubated with adriamycin. PML and PML-RARa showed basal serine 38 phosphorylation, which was further stimulated after prolonged adriamycin treatment for 16 h (Figure 4c ). However, induction of DNA damage for a short period of only 4 h allowed inducible PML phosphorylation, whereas the PML-RARa fusion protein remained unphosphorylated. Despite this remarkable difference in the kinetics of PML-RARa phosphorylation, this experiment also showed the increased stability of PML-RARa under conditions of DNA damage or HIPK2 expression. This stabilization seems to be independent from association with HIPK2, as coimmunoprecipitation experiments failed to reveal interaction between PML-RARa and HIPK2 under the conditions used (Supplementary Figure 4) . Further immunoblot experiments revealed that HIPK2 or DNA damage enhanced the SUMO modification of (HIPK2DN) were coexpressed with PML-IV. Lysates were analysed for adequate protein expression (lower) or subjected to coimmunoprecipitation with aPML antibodies, followed by immunoblotting. The position of a nonspecific band is shown (c) HIPK2 and PML-IV were radiolabelled by in vitro transcription/translation and incubated at the indicated combinations. After immunoprecipitation with aFlag antibodies and intense washing of the immunoprecipitate, samples were resolved on SDS-PAGE and analysed by autoradiography. The arrows point to HIPK2 and PML, respectively, an adequate negative control showed no binding (data not displayed). (d) U2OS cells were transfected to express GFP-HIPK2 along with PML-IV. GFP-HIPK2 was detected by the intrinsic fluorescence of GFP (green), indirect immunofluorescence was used to detect colocalization of HIPK2 with PML (red), which was detected with PML antibodies by confocal microscopy. Overlapping localization is shown in yellow, the bar corresponds to 10 mm. The lower right quadrant is a phase contrast picture of the analysed cell. Regulation of PML tumor suppressor E Gresko et al ( Figure 5b ). To test whether increased PML SUMOylation depends on its phosphorylation at the N terminus, DNA damage-induced SUMOylation was compared between PML-IV and its phosphorylation-defective or phosphomimetic mutants. In the phosphomimetic mutant, serines 8, 36 and 38 were replaced by glutamic acid (PML-IV 3S/E), in the phosphorylation-deficient mutant, serine 38 plus both of its neighboring serines and serine 8 were replaced by alanins (PML-IV 4S/A). Cells were transfected to express these PML variants either alone or together with His-tagged SUMO and HIPK2. Although DNA damage-triggered stabilization was unaffected in the phosphorylation-defective mutant, its SUMOylation was significantly impaired (Figure 5c ). To support these results by an independent experimental approach, a fraction of the lysates was purified under denaturing conditions on Ni-NTA columns, followed by the analysis of SUMOylated proteins in the eluate by immunoblotting (Figure 5d ). These experiments support the finding of a significantly reduced SUMOylation of the PML-IV 4S/A mutant, showing that HIPK2-mediated modification of the N-terminal serines in PML contributes to its DNA damage-induced SUMOylation.
PML phosphorylation is required for its ability to synergize with HIPK2 for the induction of cell death Does the phosphorylation of PML affect its ability to localize to PML-NBs and to recruit HIPK2? To address this question, cells were transfected to express GFPtagged HIPK2 with PML-IV and phosphomimetic or phosphorylation-deficient mutants. Immunofluorescence analysis revealed no influence of the PML phosphorylation sites on the intranuclear distribution of PML into PML-NBs (Figure 6a ). The PML-IV 4S/A protein showed a fully intact HIPK2 recruitment capacity, suggesting that transient PML phosphorylation is not essential for this process. In contrast, the PML-IV 3S/E mutant showed a partially impaired HIPK2 recruitment and also led to the occurrence of unrecruited HIPK2 in a plethora of microspeckles that are much smaller than the typical HIPK domains.
As PML cooperates with death-inducing factors, such as p53 for the induction of apoptosis, the three PML mutants were compared for their ability to regulate HIPK2-induced cell death. Cells were transfected to express HIPK2 either alone or together with each of the PML-IV variants. Although expression of PML alone remained without any effects on cell viability Figure 5) , HIPK2 strongly increased adriamycin-induced cell death (Figure 6b ). The detrimental effect of HIPK2 was further boosted by PML-IV, indicating that HIPK2 and its substrate protein cooperate for the induction of cell death. The PML-IV 4S/A mutant partially inhibited HIPK2-induced cell death, showing that HIPK2-mediated phosphorylation of PML-IV contributes to cell death induction by this kinase. Also the phosphomimetic PML-IV mutant failed to support the deleterious activity of HIPK2, which may be due to the incomplete PML-NB recruitment and aberrant localization of the kinase. In summary, our data show that HIPK2-mediated phosphorylation of PML at N-terminal serines contributes to the control of its SUMOylation status and its ability to synergize with HIPK2 for the induction of cell death.
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Discussion
The analysis of the three-dimensional distribution pattern of PML and HIPK2 revealed HIPK2 in the center of the PML-NBs with the PML protein mostly localizing in the periphery. These results are in Regulation of PML tumor suppressor E Gresko et al agreement with electron microscopy studies, which have shown that PML-NBs are composed of a ringlike protein structure with PML in an outer ring and a PML negative hollow in the center of the body (Boisvert et al., 2000) . The distinct localization and limited interacting surface between both proteins may also explain the binding of a very small fraction of PML to HIPK2. These results also support the idea that many PML interactors do not associate stoichiometrically but rather transiently within a subset of PML-NBs, where PML provides a catalytic surface (Borden, 2008) . gel electrophoresis, followed by semidry western blotting to a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Proteins were detected with specific antibodies by enhanced chemiluminescence.
In vitro kinase assays Recombinant GST and GST-PML proteins were expressed in Escherichia coli and purified by standard protocols. Flag-HIPK2 and Flag-HIPK2 K221A were isolated from transfected cells by immunoprecipitation. The beads were washed in adequate buffers and incubated with purified, recombinant GST proteins together with 20 mM ATP and 10 mCi g 32 P-ATP in 20 ml of kinase reaction buffer (30 mM HEPES/KOH pH 7.4, 25 mM b-glycerophosphate, 2 mM DTT, 20 mM MgCl 2 , 0.1 mM sodium vanadate) for 30 min at 30 1C. The reaction was stopped by adding SDS sample buffer and proteins were analysed by SDS-polyacrylamide gel electrophoresis and autoradiography.
Immunofluorescence U2OS cells were fixed for 1 min at À20 1C with methanol/aceton (1:1), air-dried, rehydrated with phosphate-buffered saline, blocked with goat serum and stained with the respective primary antibodies. These were detected with appropriate secondary antibodies that were coupled to Cy3 or Cy5. Nuclear DNA was detected by staining with DAPI or Hoechst 33342. Image stacks were recorded on a Zeiss LSM 510 laser scanning microscope using the laser wavelength 488 nm (Argon) and 543 nm (HeNe). Images were taken at a Z-step rate of 0.2 mm. Three-dimensional images of stacks were created by Imaris software (Bitplane AG). For surface rendering of three-dimensional objects, a minimal equal intensity threshold was set for HIPK2 and PML-IV to remove the nucleoplasmic signals.
Mass spectrometry
In vitro phosphorylated GST-PML (1-130) or GST-PML (1-130) S38A was precipitated with chloroform/methanol, solubilized, reduced and alkylated. Following trypsin cleavage, peptides were analysed by capillary liquid chromatography tandem mass spectrometry (LC-MS/MS) on a 4000 Q Trap (MDS Sciex, Concord, Ontario, Canada) in the informationdependent acquisition mode as described earlier (Hess et al., 2008) . The MS/MS spectra were compared with the program Mascot (Perkins et al., 1999) against the protein sequence database UNIPROT-12.0 and the identified phosphopeptides were evaluated manually.
Detection of cell death
One day after transfection of HS27 cells, adriamycin (0.5 mg/ml) was added for 42 h and cells were collected by centrifugation. The cell pellet was resuspended in 1 ml 1 Â FACS (fluorescence-activated cell sorting) buffer (10 mM HEPES pH 7.4, 140 mM NaCl and 2.5 mM CaCl 2 ), pelleted by centrifugation and resuspended in 400 ml FACS buffer, followed by transfer to cytometer tubes. Annexin-V-FITC solution (20 ml) (Becton Dickinson) was added to each sample and incubated for 10 min in the dark. Following addition of 500 ml of 1Â FACS buffer to reach the appropriate cell concentration, 10 000 events were measured in the FACSCalibur (Becton Dickinson, Heidelberg, Germany) flow cytometer (150-300 events per second).
